Horizon scanning implanted biosensors in personalising breast cancer management: First pilot study of breast cancer patients views

BACKGROUND Management of cancer patients in the current era of COVID-19 pandemic poses a significant challenge on health care systems. OBJECTIVE We explored the views of oncologists for the management of breast cancer patients during COVID-19 pandemic. METHODS A web-based questionnaire using SurveyMonkey was submitted to licensed oncologists involved in breast cancer management in Saudi Arabia, Egypt and United Arab Emirates. The survey focused on characteristics of participants, infection risk among cancer patients and possible treatment modifications related to different types of breast cancer RESULTS The survey was completed by 82 participants. For early HR positive, HER2-negative breast cancer,74.4% supported using neoadjuvant hormonal therapy in selected patients, and 58.0% preferred giving 6 over 8 cycles of adjuvant chemotherapy when indicated. Only 42.7% preferred CDK4/6 inhibitor with hormonal therapy as first line in all patients with metastatic HR-positive disease. 67.1% of participants supported using adjuvant trastuzumab for 6 instead of 12 months in selected patients with HER2-positive breast cancer. For metastatic HER2-positive, HR-positive breast cancer, 80.5% of participants supported the use of hormonal therapy with dual anti-HER2 blockade in selected patients. The preferred choice of 1st line treatment in metastatic triple negative patients with BRCA mutation and PDL1<1%, was PARP inhibitor according to 42.5% of the participants, and atezolizumab with nabpaclitaxel if the PDL1>1% according to 70.4% of the participants. CONCLUSIONS Several modifications in breast cancer management is supported by the survey participants. These modifications need to be discussed on local basis taking into account the local infrastructure and available resources. CLINICALTRIAL none

Download Full-text

Upper limb lymphedema related to breast cancer therapy: incidence, risk factors, diagnostic techniques, risk reduction and optimal management

International Surgery Journal ◽

10.18203/2349-2902.isj20184636 ◽

2018 ◽

Vol 5 (11) ◽

pp. 3633

Author(s):

Hatem A. Saleh ◽

Tarek M. Rageh ◽

Suzan A. Alhassanin ◽

Mohamed A. Megahed

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Cancer Patients ◽

Upper Limb ◽

Diagnostic Techniques ◽

Breast Cancer Patients ◽

Breast Cancer Therapy ◽

Cancer Management ◽

Breast Cancer Management ◽

Incidence Risk

Background: Lymphedema remains to be a great source of morbidity for breast cancer survivors. The aim of this work is to study upper limb lymphedema following breast cancer therapy for breast cancer patients regarding its incidence, risk factors, diagnostic techniques, risk reduction and optimal management.Methods: This prospective study was done on two hundred breast cancer patients who underwent breast cancer management. The study was done in the period between May 2016 and July 2018. Exclusion criteria were Male patients, Female patients with metastatic breast cancer and who already had upper limb lymphedema before breast cancer management. All patients underwent follow up for incidence, risk factors, diagnostic techniques and management of lymphedema. Statistical analysis used: The collected data were organized, tabulated and statistically analyzed using SPSS softwareResults: The incidence of lymphedema was (18 %) distributed as follow: grade I = 55.6%, grade II = 33.3%, grade III = 11.1 % and grade IV = 0 %. The most relevant risk factors for development of lymphedema were: age between 41 and 50 years and diabetes mellitus. Higher incidence of pain (66.7%) and restricted motion (61.1%) were observed in lymphedema cases.Conclusions: Old (41:50 years) and diabetic patients are at the highest risk for developing lymphedema. Breast cancer patients of stage IIIB who had undergone modified radical mastectomy or who developed postoperative seroma are at higher risk for developing lymphedema. Physical exercises and compression garment are important part of treatment plan.

Download Full-text

Updates in COVID-19 Related Lymphadenopathy - Frequent Deep Axillary Location and Possible Contralateral Involvement

International Journal of Innovative Research in Medical Science ◽

10.23958/ijirms/vol06-i10/1233 ◽

2021 ◽

Vol 6 (10) ◽

pp. 725-730

Author(s):

Pintican Roxana ◽

Duma Magdalena ◽

Szep Madalina ◽

Schiau Calin ◽

Feier Diana ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Emotional Stress ◽

Side Effect ◽

Breast Cancer Patients ◽

Oncology Patients ◽

Axillary Lymphadenopathy ◽

Cancer Management ◽

Breast Cancer Management

Ipsilateral axillary lymphadenopathy related to COVID-19 vaccine was reported as a side effect and started to raise diagnostic dilemmas especially in oncology patients. Breast cancer patients are particularly prone to this benign pitfall that may result in unfortunate management changing or unnecessary biopsy, both causing additional emotional stress for the patients. We present three cases with axillary lymphadenopathy and one with axillary and bilateral supraclavicular lymphadenopathy, and focus on what haven’t been reported yet: the deep and more superior location for the axillary lymphadenopathy and the possibility of contralateral lymphadenopathy secondary to COVID-19 vaccine. Their implication in breast cancer management will also be briefly discussed.

Download Full-text

Possible Association of Typhoon Hagibis and the COVID-19 Pandemic on Patient Delay in Breast Cancer Patients: a case report

10.22541/au.163939469.98008345/v1 ◽

2021 ◽

Author(s):

Yudai Kaneda ◽

Akihiko Ozaki ◽

Masahiro Wada ◽

Tomohiro Kurokawa ◽

Toyoaki Sawano ◽

...

Keyword(s):

Breast Cancer ◽

Case Report ◽

Cancer Patient ◽

Breast Cancer Patient ◽

Patient Care ◽

Cancer Patients ◽

Initial Presentation ◽

Breast Cancer Patients ◽

Cancer Management ◽

Breast Cancer Management

Little is known on how disasters interact in their impacts on patient care. We experienced a breast cancer patient whose initial presentation was delayed for two years due to the COVID-19 pandemic and Typhoon Hagibis. Increasing awareness is needed on the combined impacts of disasters on breast cancer management.

Download Full-text

Review of Clinical Studies of CA 27.29 in Breast Cancer Management

The International Journal of Biological Markers ◽

10.1177/172460089901400107 ◽

1999 ◽

Vol 14 (1) ◽

pp. 36-39 ◽

Cited By ~ 12

Author(s):

R.A. Beveridge

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Critical Review ◽

Early Stage ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Review Of The Literature ◽

Cancer Management ◽

Breast Cancer Management

A critical review of CA 27.29 and CA 15-3 is performed in this paper. A review of the literature is undertaken. A review of the FDA submissions for 27.29 for both early stage and monitoring metastatic breast cancer patients is reviewed.

Download Full-text

Creating Synthetic Patients to Address Interoperability Issues: A Case Study with the Management of Breast Cancer Patients

Studies in Health Technology and Informatics - Integrated Citizen Centered Digital Health and Social Care ◽

10.3233/shti200718 ◽

2020 ◽

Author(s):

Akram Redjdal ◽

Jacques Bouaud ◽

Gilles Guézennec ◽

Joseph Gligorov ◽

Brigitte Seroussi

Keyword(s):

Breast Cancer ◽

Knowledge Base ◽

Cancer Patients ◽

Decision Rules ◽

Clinical Decision ◽

Patient Data ◽

Tumor Board ◽

Breast Cancer Patients ◽

Cancer Management ◽

Breast Cancer Management

Interoperability issues are common in biomedical informatics. Reusing data generated from a system in another system, or integrating an existing clinical decision support system (CDSS) in a new organization is a complex task due to recurrent problems of concept mapping and alignment. The GL-DSS of the DESIREE project is a guideline-based CDSS to support the management of breast cancer patients. The knowledge base is formalized as an ontology and decision rules. OncoDoc is another CDSS applied to breast cancer management. The knowledge base is structured as a decision tree. OncoDoc has been routinely used by the multidisciplinary tumor board physicians of the Tenon Hospital (Paris, France) for three years leading to the resolution of 1,861 exploitable decisions. Because we were lacking patient data to assess the DESIREE GL-DSS, we investigated the option of reusing OncoDoc patient data. Taking into account that we have two CDSSs with two formalisms to represent clinical practice guidelines and two knowledge representation models, we had to face semantic and structural interoperability issues. This paper reports how we created 10,681 synthetic patients to solve these issues and make OncoDoc data re-usable by the GL-DSS of DESIREE.

Download Full-text